With 2.08 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.82 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $8.82 whereas the lowest price it dropped to was $8.575. The 52-week range on BHC shows that it touched its highest point at $11.46 and its lowest point at $5.57 during that stretch. It currently has a 1-year price target of $10.17. Beta for the stock currently stands at 0.90.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BHC was up-trending over the past week, with a rise of 0.23%, but this was down by -16.97% over a month. Three-month performance surged to 6.48% while six-month performance rose 26.05%. The stock gained 23.37% in the past year, while it has gained 8.60% so far this year. A look at the trailing 12-month EPS for BHC yields -1.62 with Next year EPS estimates of 4.10. For the next quarter, that number is 0.69. This implies an EPS growth rate of 12.75% for this year and 4.68% for next year. EPS is expected to grow by 2.60% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 32.76%.
Float and Shares Shorts:
At present, 365.24 million BHC shares are outstanding with a float of 356.59 million shares on hand for trading. On 2024-04-15, short shares totaled 20.71 million, which was 565.00003 higher than short shares on 1710460800. In addition to Mr. Thomas J. Appio as the firm’s CEO & Director, Mr. John S. Barresi serves as its Senior VP, Controller, Chief Accounting Officer & Interim CFO.
Institutional Ownership:
Through their ownership of 0.79416 of BHC’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2023-12-31, BHC reported revenue of $2408000000.0 and operating income of $503000000.0. The EBITDA in the recently reported quarter was $839000000.0 and diluted EPS was -$0.11.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BHC since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
